Targeting p53 as a general tumor antigen.
AUTOR(ES)
Theobald, M
RESUMO
A major barrier to the design of immunotherapeutics and vaccines for cancer is the idiosyncratic nature of many tumor antigens and the possibility that T cells may be tolerant of broadly distributed antigens. We have devised an experimental strategy that exploits species differences in protein sequences to circumvent tolerance of high-affinity T cells. HLA transgenic mice were used to obtain cytotoxic T lymphocytes specific for peptides from the human p53 tumor-suppressor molecule presented in association with HLA-A2.1. Although such p53-specific cytotoxic T cells did not recognize nontransformed human cells, they were able to lyse a wide variety of human tumor cells lines, thus confirming the existence of broadly distributed determinants that may serve as targets for immunotherapy.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=40282Documentos Relacionados
- Molecular cloning of a cDNA specific for the murine p53 cellular tumor antigen.
- Analysis of recombinant DNA clones specific for the murine p53 cellular tumor antigen.
- Wild-type, but not mutant, human p53 proteins inhibit the replication activities of simian virus 40 large tumor antigen.
- Major deletions in the gene encoding the p53 tumor antigen cause lack of p53 expression in HL-60 cells.
- Expression of the mouse p53 cellular tumor antigen in monkey cells.